advertisement
Yazdani S 12
Showing records 1 to 12 | Display all abstracts from Yazdani S66619 Biometric Changes After Trabeculectomy with Contact and Non-contact Biometry
Alvani A
Optometry and Vision Science 2016; 93: 136-140
66508 The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage Glaucoma
Pakravan M
American Journal of Therapeutics 2017; 24: e676-e680
66619 Biometric Changes After Trabeculectomy with Contact and Non-contact Biometry
Pakravan M
Optometry and Vision Science 2016; 93: 136-140
66508 The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage Glaucoma
Beni AN
American Journal of Therapeutics 2017; 24: e676-e680
66619 Biometric Changes After Trabeculectomy with Contact and Non-contact Biometry
Esfandiari H
Optometry and Vision Science 2016; 93: 136-140
66508 The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage Glaucoma
Ghahari E
American Journal of Therapeutics 2017; 24: e676-e680
66619 Biometric Changes After Trabeculectomy with Contact and Non-contact Biometry
Yaseri M
Optometry and Vision Science 2016; 93: 136-140
66508 The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage Glaucoma
Varshochian R
American Journal of Therapeutics 2017; 24: e676-e680
66619 Biometric Changes After Trabeculectomy with Contact and Non-contact Biometry
Yazdani S
Optometry and Vision Science 2016; 93: 136-140
66508 The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage Glaucoma
Yazdani S; Esfandiari H
American Journal of Therapeutics 2017; 24: e676-e680
66619 Biometric Changes After Trabeculectomy with Contact and Non-contact Biometry
Ghahari E
Optometry and Vision Science 2016; 93: 136-140
66508 The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage Glaucoma
Ahmadieh H
American Journal of Therapeutics 2017; 24: e676-e680
